Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional) | PAR 19 070

Opportunity Information: Apply for PAR 19 070

The National Institutes of Health (NIH) announced this discretionary grant opportunity, PAR-19-070, titled "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)." It uses the NIH R01 research project grant mechanism and is aimed at supporting investigator-initiated research on timely, high-priority scientific questions in Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). A key feature of this announcement is that it is structured to remain current over time: NIH indicates that specific priority topics of interest will be updated and communicated through additional Notices released after the FOA, meaning applicants are expected to monitor those Notices to align proposals with the most current priorities.

The scope is broadly described as research on "current topics" in AD/ADRD rather than a single narrowly defined theme. In practice, this kind of FOA is designed to attract a wide range of projects across the AD/ADRD research landscape, potentially including basic, translational, clinical, behavioral, health services, and population-oriented studies, depending on what NIH later highlights in the Notices. The "Clinical Trial Optional" designation means applicants may propose either studies that include a clinical trial component or projects that do not involve a clinical trial; both types of applications are allowed as long as they fit NIH's stated interests and requirements.

Eligibility is expansive and includes many types of domestic U.S. organizations and governments, as well as certain non-U.S. entities. Eligible applicants listed include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories as specified); for-profit organizations other than small businesses; small businesses; and other unspecified eligible entities. The FOA also explicitly calls out additional eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-domestic (non-U.S.) entities/foreign organizations. This breadth signals NIH's intent to encourage participation from a diverse set of institutions, including those serving underrepresented communities and organizations positioned to conduct community-engaged or population-relevant AD/ADRD research.

From an administrative standpoint, the opportunity is categorized under Health and is associated with CFDA numbers 93.853 and 93.866, which correspond to NIH research assistance programs. The FOA was created on 2018-11-16, and the original closing date shown in the source data is 2021-11-12. The listing does not provide an award ceiling or expected number of awards in the fields shown, which often means applicants need to consult the full FOA text and any associated NIH Institute/Center guidance for budget expectations, project period norms, and the anticipated scale of funding.

Overall, this FOA is essentially a standing invitation for R01 applications that tackle NIH-identified, fast-moving priorities in Alzheimer's and related dementias, with the details of those priorities being periodically refreshed through subsequent Notices. Applicants considering this opportunity would typically focus on developing a strong R01-style research plan aligned to the latest posted priority topics, ensure they select the appropriate clinical trial designation based on study design, and confirm eligibility and administrative requirements based on NIH guidance associated with PAR-19-070.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853, 93.866.
• This funding opportunity was created on 2018-11-16.
• Applicants must submit their applications by 2021-11-12. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 19 070

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: